Seagen Names David R. Epstein as Chief Executive Officer and Director
Seagen Inc. (Nasdaq: SGEN) today announced that its Board of Directors has appointed David R. Epstein as Chief Executive Officer (CEO) and a member of the Board of Directors. Mr. Epstein brings more than 30 years of experience in the biopharmaceutical industry, including more than 25 years at Novartis where he built its oncology business unit from initiation to second largest in the world and then served as CEO of Novartis Pharmaceuticals, a division of Novartis AG. More recently, he was executive partner at Flagship Pioneering. In addition, Seagen announced that Roger Dansey, M.D., who has served as Seagen’s Chief Medical Officer (CMO) since 2018 and as Interim CEO since May 2022, has been appointed President, Research and Development. In this new role, Dr. Dansey will continue to serve as CMO reporting to David.
“Following a comprehensive search process, the Board selected David to serve as Seagen’s next CEO. He shares Seagen’s belief that our future is bright as we continue to build world-class capabilities in order to develop and commercialize new innovative treatments that improve the lives of patients with cancer. David’s demonstrated ability to build and scale a global oncology business, his experience in both large multi-faceted organizations and small biotechnology startups, combined with deep oncology knowledge, provide the strategic and operational expertise needed to lead Seagen to the next level,” said Felix J. Baker, Ph.D., Chair of the Board. “We are extremely grateful for Roger’s successful leadership and dedication as interim CEO. We look forward to Roger being able to focus his efforts on further strengthening our early research efforts, as he has successfully done for development, and driving the innovative engine that has been the heart of Seagen to have an even greater impact on cancer patients in the future.”
Mr. Epstein said, “I have long admired Seagen as a leader in the development and commercialization of transformative cancer therapies. Seagen is a pioneer in antibody-drug conjugate (ADC) technology with a portfolio of four approved medicines, a diverse pipeline of promising programs, and a science-driven, patient-first culture. I am honored to become CEO and work with the experienced team to further deliver on Seagen’s mission to make a meaningful difference so that people who have been diagnosed with cancer can live better lives.”
“I welcome David to the Seagen team and look forward to working closely with him as we continue to bring forward novel ADCs and other targeted treatments for cancer patients,” said Dr. Dansey. “I am excited to bring my passion for science and innovation to my expanded role overseeing research and development as we continue to deliver on the full potential of our pipeline and programs.”
About David R. Epstein
David R. Epstein has more than 30 years of drug development, deal making, commercialization and people leadership experience on a global scale. Most recently, he was executive partner at Flagship Pioneering, a builder of breakthrough bioplatform companies. From 2010 to mid-2016 he served as CEO of Novartis Pharmaceuticals, a division of Novartis AG. Previously, David started and led Novartis’ Oncology and Molecular Diagnostic units. Over the course of his career, he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec, Tasigna, Gilenya, Cosentyx and Entresto. Mr. Epstein holds a B.S. Degree in Pharmacy from Rutgers University College of Pharmacy and an MBA in Finance and Marketing from the Columbia University Graduate School of Business.
About Roger Dansey, M.D.
Dr. Dansey joined Seagen as CMO in 2018, bringing extensive experience in cancer drug development. Previously, he was Therapeutic Area Head for Late-Stage Oncology at Merck & Co., Inc., where he was responsible for registration efforts for Keytruda (pembrolizumab) across multiple tumor types. Earlier in his career, Dr. Dansey was the Vice President of Oncology Clinical Research at Gilead Sciences and the Global Development Lead for Xgeva (denosumab) at Amgen, where he held multiple roles in oncology and hematology.
Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit and follow @SeagenGlobal on Twitter.
Certain of the statements made in this press release are forward looking, such as those, among others, relating to the potential of Seagen’s pipeline and programs, and the company’s efforts to build world-class capabilities in order to develop and commercialize new innovative treatments and to bring forward novel ADCs and other targeted treatments for cancer patients. Factors that may cause such a difference include, without limitation, the difficulty and uncertainty of pharmaceutical product development, the risk of adverse events or safety signals, the inability to show sufficient activity in clinical trials and the possibility of adverse regulatory actions. More information about the risks and uncertainties faced by Seagen is contained under the caption “Risk Factors” included in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Senior Vice President, Investor Relations and Corporate Communications
Douglas Maffei, Ph.D.
Vice President, Investor Relations
Vice President, Corporate Communications
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verimatrix Launches VCAS Monitoring in the Cloud8.12.2022 19:45:00 EET | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced general availability of its latest cloud-based content protection monitoring capabilities through its Video Content Authority System (VCAS). These newest additions to the Verimatrix VCAS solution bring the option of best of cloud-enabled monitoring capabilities to the on-premises Verimatrix customers of today and tomorrow. A unique mix of cloud-based technologies that offers the video content industry new and easy everywhere-access to subscriber experiences and trends, the latest Verimatrix VCAS monitoring is available to current and prospective clients – prioritizing the need to powerfully mix intelligence with revenue preservation and ease of use amid today’s ever-increasing threat of bad actors. It also helps maximize performance and minimize delivery latency. “As one of the industry’s most trusted and long-serving video con
AGC to Exhibit Next-generation Mobility-enabling Products & Technologies at CES20238.12.2022 18:00:00 EET | Press release
AGC, the provider of a wide range of solutions from automotive and display glass to the cutting-edge materials essential for next-generation mobility, will exhibit at CES2023, the world's leading technology trade show, being held in Las Vegas during January 3-8, 2023. The 3rd and 4th will be reserved for media and pre-show keynotes; the fair will be open to the public from the 5th. The company will exhibit 17 of its products, including several brand new releases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221204005064/en/ AGC‘s booth at CES2023 (#4377, Vehicle Tech & Advanced Mobility, LVCC - West Hall) (Graphic: Business Wire) AGC has been a leading manufacturer of architectural, automotive and display glass for more than 110 years, supplying high-quality products worldwide. Today, the company leverages its technological expertise in the fields of glass, electronics, chemicals, and ceramics to provide a variety of cutti
ABS Explores Future of Cutting-Edge Maritime Tech in Broad-Reaching Report8.12.2022 18:00:00 EET | Press release
Will autonomous vessels dominate the oceans? Can artificial intelligence design an optimized offshore asset? Is nuclear power the ultimate energy source of the future? These are some of the questions facing maritime industry leaders as a wave of new technologies is poised to revolutionize the sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221207005783/en/ Cover Image: ABS Technology Trends (Graphic: Business Wire) ABS recognizes the coming surge of innovations and is charting a course for the future of marine and offshore technologies with a new report, Technology Trends: Exploring the Future of Maritime Innovation. The publication, launched at the ABS Hellenic Technical Committee, offers an executive glimpse into the future of advanced marine and offshore technologies, laying out a vision and timeline for key technological milestones on the journey to net-zero emissions and digitalization. “Innovation in the maritim
Metropolitan Premium Properties and Mallorca Properties close Dubai’s biggest residential land transaction for AED 690M8.12.2022 17:50:00 EET | Press release
Metropolitan Premium Properties (MPP) – a full-service real estate agency and the Metropolitan Group’s flagship property company, together with Mallorca Properties, a boutique commercial real estate firm specializing in high-end and private real estate investment opportunities, have closed Dubai’s single biggest residential land transaction to date – an AED 690M (USD 187.6M) deal for three plots at Dubai Marina. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005588/en/ Ahmed Abou El Naga, Head of Institutional Sales of Metropolitan Group (Photo: AETOSWire) The built-up area of the transaction is over 1.7 million sq. ft. and the total seafront plot is over 100,000 sq. ft. directly on Dubai’s most luxurious marina with unobstructed views of the sea, Dubai Eye and Palm Jumeirah. Ultra-luxury apartments and penthouses are expected to be developed on the plots which were sold to a leading Dubai-based real estate developer.
New Research Reveals Supply Chain Resiliency and Agility are Key Drivers for Process Automation8.12.2022 17:00:00 EET | Press release
Precisely, the global leader in data integrity, in collaboration with SAPinsider, today announced the results of new global research that highlights the importance of process automation in building robust supply chains. Findings from the new benchmark report, Process Automation in Supply Chain, show that 51% of respondents cite resiliency as the top supply chain concern driving the need for process automation, with agility close behind at 46%. A backdrop of disruptive world events means businesses are increasingly battling against global supply chain disruption, as well as mounting pressures to keep pace with changing consumer preferences for digital, local, and sustainable goods – resulting in an urgent need for supply chain transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005434/en/ 51% of business leaders cite resiliency as top supply chain concern driving need for process automation (Graphic: Business
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom